VX-548
Acute Pain
Key Facts
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a premier biotechnology company that has revolutionized treatment for cystic fibrosis with its portfolio of CFTR modulators, generating billions in annual revenue. The company has successfully expanded beyond CF into gene editing with CTX001 for sickle cell disease and beta thalassemia, and is advancing programs in pain, diabetes, and other serious diseases. With a strong commercial franchise and robust pipeline, Vertex represents one of the most successful biotech companies in translating scientific innovation into life-changing medicines.
View full company profileAbout XOMA
XOMA has strategically transformed from a traditional drug developer into a capital-efficient royalty aggregator, building a diversified portfolio of economic interests in innovative therapeutic candidates. The company's model mitigates traditional biotech risks by acquiring rights to potential future payments from partnered programs, many of which are advanced by well-funded biopharma partners. XOMA's deep expertise in antibody science informs its investment decisions, targeting programs with validated biology and significant commercial potential across various therapeutic areas.
View full company profileTherapeutic Areas
Other Acute Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Maxigesic® Oral Tablets | AFT Pharmaceuticals | Approved/Commercial |
| Maxigesic® Rapid (ODT) | AFT Pharmaceuticals | Launched |
| Maxigesic® Intranasal Formulation | AFT Pharmaceuticals | Pre-clinical |